Howard, S. C. in Abeloff’s Clinical Oncology (eds Niederhuber, J. E. et al.) 572–580 (Elsevier, 2020).

Howard, S. C., Jones, D. P. & Pui, C. H. The tumor lysis syndrome. N. Engl. J. Med. 364, 1844–1854 (2011).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharman, J. P. et al. A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies. EJHaem 3, 492–506 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Durani, U. & Hogan, W. J. Emergencies in haematology: tumour lysis syndrome. Br. J. Haematol. 188, 494–500 (2020).

Article  PubMed  Google Scholar 

Cairo, M. S. & Bishop, M. Tumour lysis syndrome: new therapeutic strategies and classification. Br. J. Haematol. 127, 3–11 (2004).

Article  PubMed  Google Scholar 

Mehta, R. L. et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11, R31 (2007).

Article  PubMed  PubMed Central  Google Scholar 

Durani, U., Shah, N. D. & Go, R. S. In-hospital outcomes of tumor lysis syndrome: a population-based study using the national inpatient sample. Oncologist 22, 1506–1509 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Howard, S. C., Trifilio, S., Gregory, T. K., Baxter, N. & McBride, A. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review. Ann. Hematol. 95, 563–573 (2016).

Article  CAS  PubMed  Google Scholar 

Kaur, V. & Swami, A. Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: a case report. J. Oncol. Pharm. Pract. 23, 235–239 (2017).

Article  PubMed  Google Scholar 

Tam, C. S., Seymour, J. F. & Roberts, A. W. Progress in BCL2 inhibition for patients with chronic lymphocytic leukemia. Semin. Oncol. 43, 274–279 (2016).

Article  CAS  PubMed  Google Scholar 

Kaur, V., Mehta, P., Johnsurd, J. & Govindarajan, R. Ibrutinib-associated tumor lysis syndrome in a patient with chronic lymphocytic leukemia. Blood 124, 3503–3505 (2014).

Article  CAS  PubMed  Google Scholar 

Alqurashi, R. M., Tamim, H. H., Alsubhi, Z. D., Alzahrani, A. A. & Tashkandi, E. Tumor lysis syndrome in patients with solid tumors: a systematic review of reported cases. Cureus 14, e30652 (2022).

PubMed  PubMed Central  Google Scholar 

Wossmann, W., Schrappe, M., Meyer, U., Zimmermann, M. & Reiter, A. Incidence of tumor lysis syndrome in children with advanced stage Burkitt’s lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann. Hematol. 82, 160–165 (2003).

Article  CAS  PubMed  Google Scholar 

Montesinos, P. et al. Tumor lysis syndrome in patients with acute myeloid leukemia: identification of risk factors and development of a predictive model. Haematologica 93, 67–74 (2008).

Article  CAS  PubMed  Google Scholar 

Howard, S. C. & Pui, C. H. Pitfalls in predicting tumor lysis syndrome. Leuk. Lymphoma 47, 782–785 (2006).

Article  CAS  PubMed  Google Scholar 

Hummel, M. et al. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase. Eur. J. Haematol. 75, 518–521 (2005).

Article  PubMed  Google Scholar 

Kelkar, N. & Wang, J. Clinical features and outcomes of tumor lysis syndrome in patients with gastrointestinal cancers. J. Clin. Oncol. 40, https://doi.org/10.1200/JCO.2022.40.4_suppl.655 (2022).

Jallad, B. et al. Tumor lysis syndrome in small cell lung cancer: a case report and review of the literature. Onkologie 34, 129–131 (2011).

Article  PubMed  Google Scholar 

Jeha, S. Tumor lysis syndrome. Semin. Hematol. 38, 4–8 (2001).

Article  CAS  PubMed  Google Scholar 

Ji, J. et al. A pharmacokinetic/pharmacodynamic model of tumor lysis syndrome in chronic lymphocytic leukemia patients treated with flavopiridol. Clin. Cancer Res. 19, 1269–1280 (2013).

Article  CAS  PubMed  Google Scholar 

Williams, S. M. & Killeen, A. A. Tumor lysis syndrome. Arch. Pathol. Lab. Med. 143, 386–393 (2019).

Article  CAS  PubMed  Google Scholar 

Cairo, M. S. et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 109, 2736–2743 (2007).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cairo, M. S. Recombinant urate oxidase (rasburicase): a new targeted therapy for prophylaxis and treatment of patients with hematologic malignancies at risk of tumor lysis syndrome. Clin. Lymphoma 3, 233–234 (2003).

Article  PubMed  Google Scholar 

Rios-Olais, F. A., Gil-Lopez, F., Mora-Canas, A. & Demichelis-Gomez, R. Tumor lysis syndrome is associated with worse outcomes in adult patients with acute lymphoblastic leukemia. Acta Haematol. https://doi.org/10.1159/000534453 (2023).

Article  PubMed  Google Scholar 

Xue, Y. et al. Clinical characteristics of tumor lysis syndrome in childhood acute lymphoblastic leukemia. Sci. Rep. 11, 9656 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mato, A. R. et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk. Lymphoma 47, 877–883 (2006).

Article  PubMed  Google Scholar 

Biro, E. et al. Daily serum phosphate increase as early and reliable indicator of kidney injury in children with leukemia and lymphoma developing tumor lysis syndrome. Pediatr. Nephrol. 38, 3117–3127 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Cairo, M. S., Coiffier, B., Reiter, A. & Younes, A. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br. J. Haematol. 149, 578–586 (2010).

Article  CAS  PubMed  Google Scholar 

Harmon, J. et al. Liver metastasis as an independent predictor for mortality in patients who developed tumor lysis syndrome: analysis of 132 patients with solid tumors. J. Clin. Oncol. 36, https://doi.org/10.1200/JCO.2018.36.15_suppl.e18766 (2018).

Zhang, Q. et al. Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma. Front. Immunol. 14, 1125357 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Abdel-Nabey, M. et al. Tumor lysis syndrome, acute kidney injury and disease-free survival in critically ill patients requiring urgent chemotherapy. Ann. Intensive Care 12, 15 (2022).

Article  CAS  PubMed Central  Google Scholar 

Dinnel, J., Moore, B. L., Skiver, B. M. & Bose, P. Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy. Core Evid. 10, 23–38 (2015).

PubMed  PubMed Central  Google Scholar 

Cheuk, D. K., Chiang, A. K., Chan, G. C. & Ha, S. Y. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.Cochrane Database Syst. Rev. 6, CD006945 (2010).

Google Scholar 

Gopakumar, K. G. et al. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: analysis from a resource-limited setting. Pediatr. Blood Cancer 65, e27401 (2018).

Article  PubMed  Google Scholar 

Gopakumar, K. G., Thankamony, P., Seetharam, S. & Kusumakumary, P. Treatment of tumor lysis syndrome in children with leukemia/lymphoma in resource-limited settings — efficacy of a fixed low-dose rasburicase.Pediatr. Hematol. Oncol. 34, 206–211 (2017).